Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,834 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Hans van Houte sold 2,834 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $26.28, for a total value of $74,477.52. Following the completion of the sale, the chief financial officer owned 47,514 shares of the company’s stock, valued at $1,248,667.92. This trade represents a 5.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, August 4th, Hans van Houte sold 4,761 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock traded down $1.10 on Monday, reaching $25.70. 2,348,532 shares of the company were exchanged, compared to its average volume of 2,495,734. The company’s 50-day moving average is $24.98 and its two-hundred day moving average is $20.20. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 11.13 and a beta of 1.82. Nurix Therapeutics, Inc. has a 1-year low of $11.67 and a 1-year high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. As a group, sell-side analysts forecast that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus set a $41.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, October 13th. Needham & Company LLC reissued a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Morgan Stanley raised their target price on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen raised Nurix Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.79.

Institutional Trading of Nurix Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Nurix Therapeutics in the second quarter valued at about $212,769,000. Perceptive Advisors LLC increased its position in Nurix Therapeutics by 4.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock worth $57,519,000 after purchasing an additional 155,000 shares during the last quarter. Trails Edge Capital Partners LP acquired a new position in Nurix Therapeutics in the 2nd quarter worth about $38,166,318. Bank of America Corp DE purchased a new stake in shares of Nurix Therapeutics during the 2nd quarter worth about $20,429,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Nurix Therapeutics by 81.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 780,696 shares of the company’s stock worth $12,094,000 after purchasing an additional 349,710 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.